Acura Pharmaceuticals, Inc. (ACUR)
| Market Cap | 6.84M |
| Revenue (ttm) | 4.07M |
| Net Income (ttm) | -810,000 |
| Shares Out | 32.34M |
| EPS (ttm) | -0.03 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 26 |
| Last Price | $0.3600 |
| Previous Close | $0.3200 |
| Change ($) | 0.0400 |
| Change (%) | 12.50% |
| Day's Open | 0.3751 |
| Day's Range | 0.3500 - 0.3751 |
| Day's Volume | 22,238 |
| 52-Week Range | 0.12 - 0.45 |
News
There are no news available yet.
About ACUR
Acura Pharmaceuticals, a specialty pharmaceutical company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. The company has six additional... [Read more...]
| Industry Drug Manufacturers-Specialty & Generic | Founded 1935 |
| CEO Robert Jones | Employees 12 |
| Stock Exchange OTCMKTS | Ticker Symbol ACUR |
Financial Performance
In 2019, ACUR's revenue was $2.66 million, an increase of 548.05% compared to the previous year's $410,000. Losses were -$3.77 million, -1.77% less than in 2018.